New hope for advanced cancer? first human trial of ALK201 begins
NCT ID NCT06656390
First seen Mar 16, 2026 · Last updated May 02, 2026 · Updated 8 times
Summary
This study tests a new drug called ALK201 in people with advanced solid tumors that have not responded to other treatments. The main goals are to check the drug's safety and find the best dose. About 202 adults will take part in this early-phase trial.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cancer Care Wollongong
RECRUITINGWollongong, New South Wales, 2500, Australia
Contact
-
Shanghai East Hospital
RECRUITINGShanghai, Shanghai Municipality, 200000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.